Multiple sclerosis and related disorders最新文献

{"title":"De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study","authors":"Rosaria Sacco ,&nbsp;Giulio Disanto ,&nbsp;Emanuele Pravatà ,&nbsp;Giulia Mallucci ,&nbsp;Aleksandra Maleska Maceski ,&nbsp;Jens Kuhle ,&nbsp;Claudio Gobbi ,&nbsp;Chiara Zecca","doi":"10.1016/j.msard.2024.106145","DOIUrl":"10.1016/j.msard.2024.106145","url":null,"abstract":"<div><div>Prolonged treatment with anti-CD20 antibodies can lead to hypogammaglobulinemia and increased infection risk in multiple sclerosis (MS). We investigated switch from anti-CD20 to cladribine as a strategy to prevent immunoglobulin reduction while preserving efficacy. We prospectively analysed serum IgG, IgM, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in 44 patients, 14 who were switched from anti-CD20 to cladribine and 30 continuing anti-CD20. Over 1 year, serum IgG, IgM, NfL and GFAP remained stable after switch and similar to patients continuing anti-CD20. More than 90 % of patients remained free of disease activity. Cladribine should be further explored as de-escalating agent from anti-CD20 in MS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 106145"},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences and attitudes regarding early intervention in multiple sclerosis: A systematic literature review","authors":"Sylvia Martin ,&nbsp;Ulrik Kihlbom ,&nbsp;Guido Pasquini ,&nbsp;Filippo Gerli ,&nbsp;Claudia Niccolai ,&nbsp;Sara Della Bella ,&nbsp;Emilio Portaccio ,&nbsp;Matteo Betti ,&nbsp;Maria Pia Amato ,&nbsp;Anat Achiron ,&nbsp;Alon Kalron ,&nbsp;Roy Aloni ,&nbsp;Karin Schölin Bywall","doi":"10.1016/j.msard.2024.106143","DOIUrl":"10.1016/j.msard.2024.106143","url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is a chronic inflammatory disorder affecting the brain and spinal cord, characterized by immune-mediated myelin damage. Early intervention and detection programs have emerged as promising strategies to improve patient outcomes by identifying and treating MS in its earliest stages.</div></div><div><h3>Objective</h3><div>This systematic literature review aims to provide an overview of the preferences, attitudes, and opinions of both patients and healthcare professionals regarding early intervention or early detection programs for MS.</div></div><div><h3>Methods</h3><div>A comprehensive search strategy was employed in March 2023 across multiple databases (MEDLINE, Scopus, PsyInfo, PubMed), from 1990 to 2023. A total of 38 articles were selected for analysis based on predefined inclusion and exclusion criteria.</div></div><div><h3>Results</h3><div>The majority of articles were published in recent years and represented different methods from case reports to randomized controlled trials, with fewer systematic literature reviews. Data collection approaches included patients, healthcare workers, or mixed samples with varying age ranges and gender ratios, frequently preferring women. These samples represented different preference study methods. The included studies were primarily conducted in the USA and the UK. Thematic analysis revealed several key themes : 1) differences emerged between healthcare professionals' and patients' perspectives 2) interventions for MS outside Disease-Modifying Therapies (DMTs) 3) severe side effects 4) communication, information, and knowledge 5) psychological and emotional aspects.</div></div><div><h3>Conclusions</h3><div>Understanding these diverse factors and subgroups within the MS population can inform more effective, personalized approaches to MS prevention and treatment.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 106143"},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing a multidisciplinary approach for older adults with multiple sclerosis: Geriatric neurology in practice","authors":"Mara Bahri ,&nbsp;Kristi Epstein ,&nbsp;Erin Stevens ,&nbsp;Ashley E. Rosko ,&nbsp;Sarita Maturu ,&nbsp;Yinan Zhang","doi":"10.1016/j.msard.2024.105952","DOIUrl":"10.1016/j.msard.2024.105952","url":null,"abstract":"<div><h3>Background</h3><div>Older adults with multiple sclerosis (MS) face unique challenges arising from age-related changes in MS pathophysiology and overlapping geriatric syndromes. There is a need for geriatrics-focused multidisciplinary care for the rapidly growing older MS population.</div></div><div><h3>Objective</h3><div>To design and implement a geriatric multidisciplinary clinic for older adults with MS.</div></div><div><h3>Methods</h3><div>We describe the development of a multidisciplinary approach to geriatric MS care within a single institution through the implementation of the Aging with MS Clinic. The clinic model was conceived through collaboration between neurology and geriatric medicine to provide comprehensive care for older adults with MS who are uniquely affected by overlapping symptoms of aging and MS (e.g., frailty, falls, functional decline, multiple comorbidities, polypharmacy, cognitive impairment, nutritional deficits, barriers to access healthcare). Multidisciplinary specialists were recruited to staff the clinic, and initial patient satisfaction outcomes were collected.</div></div><div><h3>Results</h3><div>The team of multidisciplinary specialists staffing the clinic consists of a MS advanced practice practitioner, MS pharmacist, physical therapist, neuropsychologist, dietitian, and social worker. A clinic template was devised where 4 patients with MS over age 60 are seen by each specialist during each half-day clinic session. Initial patient satisfaction surveys from 25 participants showed overwhelmingly positive feedback. A majority of participants (92%) agreed that the clinic was well-organized, while 92% felt they benefitted from attending. Additionally, 80% of participants reported that the clinic improved their overall quality of care.</div></div><div><h3>Conclusion</h3><div>The Aging with MS clinic outlines a model for comprehensive geriatric assessment and care in older adults with MS by a team of multidisciplinary specialists. Initial feedback from patients who attended the clinic conveyed improved quality of care.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105952"},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing consensus on lifestyle recommendations and behaviour change strategies to promote brain health-focussed care for multiple sclerosis: A modified e-Delphi study","authors":"Olivia Wills ,&nbsp;Dominique Brischetto ,&nbsp;Karen Zoszak ,&nbsp;Shoroog Allogmanny ,&nbsp;Anne-Therese McMahon ,&nbsp;Jodi Haartsen ,&nbsp;Yasmine Probst","doi":"10.1016/j.msard.2024.105949","DOIUrl":"10.1016/j.msard.2024.105949","url":null,"abstract":"<div><h3>Introduction</h3><div>Brain health is a global priority for multiple sclerosis (MS) care. This study aimed to establish consensus on internationally applicable lifestyle recommendations and behaviour change strategies to promote lifelong brain health for people living with MS.</div></div><div><h3>Methods</h3><div>A three-round, modified, e-Delphi survey was conducted. Lifestyle recommendations and behaviour change strategies were generated based on a review of the published literature, qualitative interviews, and expert feedback, respectively.</div></div><div><h3>Results</h3><div>Sixty-nine experts participated, with a final response rate of 75 %. Experts were predominantly female (<em>n</em> = 50, 72 %), 30 to 59 years of age (<em>n</em> = 54, 78 %) and worked in an academic institution (<em>n</em> = 21, 50 %). A majority (<em>n</em> = 16, 80 %) of experts with lived experience had a relapsing-remitting phenotype. Starting with 15 lifestyle recommendations, we iteratively identified new recommendations and combined existing ones, achieving consensus on 17 lifestyle recommendations among experts from healthcare, academia, research and advocacy; 16 among experts with lived experience, and 14 behaviour change strategies, presented as separate frameworks.</div></div><div><h3>Conclusions</h3><div>An e-Delphi process has established lifestyle recommendations and identified behaviour change strategies to promote brain health-focussed care for MS. Reliance on these frameworks with detailed management recommendations may help to establish consistency in lifestyle behaviour management of MS, between and within healthcare systems.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105949"},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities and their association with outcomes in the multiple sclerosis population: A rapid review","authors":"Hanna A. Frank ,&nbsp;Melissa Chao ,&nbsp;Helen Tremlett ,&nbsp;Ruth Ann Marrie ,&nbsp;Lisa M. Lix ,&nbsp;Kyla A. McKay ,&nbsp;Fardowsa Yusuf ,&nbsp;Feng Zhu ,&nbsp;Mohammad Ehsanul Karim","doi":"10.1016/j.msard.2024.105943","DOIUrl":"10.1016/j.msard.2024.105943","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Multiple sclerosis (MS) has a high comorbidity burden. Despite known associations with adverse outcomes, a comprehensive evaluation of the specific associations between individual comorbidities and disability, treatment initiation, and mortality remains underexplored. This study aimed to review and summarize existing evidence on the association between comorbidities and these three MS outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A rapid review spanning the period from January 2002 to October 2023 was conducted following the Cochrane Rapid Review Methods Group recommendations. MEDLINE, Embase, and the grey literature were searched to identify studies examining the effects of comorbidities on disability, treatment initiation, and mortality among individuals with MS. Data extraction and risk of bias assessments were systematically performed, with the Newcastle-Ottawa scale and A MeaSurement Tool to Assess systematic Reviews (AMSTAR-2) criteria for observational studies and systematic reviews respectively.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The review included 100 primary studies, encompassing 88 different comorbidities. Most study populations were between 60–80% female, with an average age of 30–45 years at study start. The majority of included studies were conducted in Europe, North America, and Asia (specifically the Middle East). Over half (66%) of specific comorbidity-outcome relationships were examined within a single study only, and just two studies examined treatment initiation as an outcome. Methods used to assess comorbidities and outcomes varied widely and included self-report measures, medical records and diagnostic codes, and standardized clinical assessments. Depression was consistently associated with greater disability (adjusted hazard ratio (aHR): 1.50–3.59) and mortality (aHR: 1.62–3.55). Epilepsy was similarly associated with increased disability (aOR: 1.13–1.77) and increased mortality (aHR: 2.23–3.85). Diabetes was generally associated with increased mortality (aHR: 1.39–1.47), but results for disability were inconsistent. Most other conditions were examined in one or two studies only or findings varied across studies, unable to collectively indicate a clear association. Although the anxiety-disability relationship was assessed by 24 studies, the findings varied in terms of the presence, direction, and strength of a possible association, requiring nuanced interpretation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This study identifies relationships between various comorbidities and three outcomes in MS, providing a foundation for future research and clinical guidelines. People with psychiatric, metabolic, and neurological conditions may be at a higher risk of MS disease progression and may therefore benefit from the targeted treatment of their comorbidities. Overall, comorbidities have varying associations with MS outcomes and individual associations require further exploration. However, there is ","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105943"},"PeriodicalIF":2.9,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple sclerosis-associated uveitis in Persian population, a multicenter study","authors":"Pasha Anvari ,&nbsp;Sahba Fekri ,&nbsp;Alireza Hedayatfar ,&nbsp;Hora Heidari ,&nbsp;SeyedehMaryam Hosseini ,&nbsp;Saeed Khamesi ,&nbsp;Kosar Kohandel ,&nbsp;Zahra Mahdizad ,&nbsp;Masoud Soheilian ,&nbsp;Mohammad Zarei ,&nbsp;Hanieh Niktinat ,&nbsp;Nazanin Ebrahimiadib","doi":"10.1016/j.msard.2024.105947","DOIUrl":"10.1016/j.msard.2024.105947","url":null,"abstract":"<div><h3>Purpose</h3><div>To report the characteristics of multiple sclerosis-associated uveitis (MSU) among the Persian population.</div></div><div><h3>Patients and methods</h3><div>Retrospective, nonrandomized, multicenter study. Epidemiological characteristics, ocular and neurologic findings, angiographic features, and visual outcomes in MSU were studied.</div></div><div><h3>Results</h3><div>92 patients (173 eyes) were included; the mean age at the time of uveitis onset was 35.9 ± 10.9 years (range; 10–60 years), 84.8 % were female, and 88.0 % had bilateral involvement. The anatomical subgroups were isolated anterior uveitis (AU) in 12.0 %, intermediate uveitis (IU) with or without AU in 84.8 % and pure retinal vasculitis in 3.3 % of patients. None of the patients were defined as having posterior or panuveitis. Uveitis had an insidious onset and chronic course in 89.1 % patients and was of granulomatous type in 81.9 %. The diagnosis of MS precedes uveitis onset in 48.8 % patients (range 1 to 35 years, median: 7 years) and was concurrent or after the uveitis onset in 52.2 % patients (range; 1 to 12 years; median: 2 years). Undifferentiated intermediate uveitis was the most common initial diagnosis (30.4 %) before MS establishment. 89.1 % of patients received at least one conventional immunotherapy agent. Peripheral retinal perivascular leakage (81.4 %) and optic disc hyperfluorescence (74.4 %) were the two most common fluorescein angiography (FA) findings The major causes of visual impairment were cataracts (52.7 %), cystoid macular edema (CME) (31.5 %), and optic neuritis (29.2 %). During an average follow-up time of 4.76 ± 3.18 years (range: 1–12 years), visual acuity improved –0.09 logMar/year and most eyes maintain relatively good visual acuity.</div></div><div><h3>Conclusion</h3><div>MSU usually presents as chronic granulomatous bilateral IU and less often isolated AU, especially in females. Retinal vasculitis can be a prominent feature. Clinically, it may resemble Undifferentiated intermediate uveitis . In geographical areas where MS is prevalent, the indication of neuroimaging should be expanded and include patients presenting with chronic granulomatous IU or AU especially if accompanied by retinal vasculitis.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105947"},"PeriodicalIF":2.9,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of epilepsy or seizure and multiple sclerosis; review of the literature with a single center experience","authors":"Furkan Saridas ,&nbsp;Gizem Mesut ,&nbsp;Rifat Ozpar ,&nbsp;Emine Rabia Koc ,&nbsp;Bahattin Hakyemez ,&nbsp;Aylin Bican Demir ,&nbsp;Omer Faruk Turan","doi":"10.1016/j.msard.2024.105948","DOIUrl":"10.1016/j.msard.2024.105948","url":null,"abstract":"<div><h3>Objectives</h3><div>There is evidence that the inflammatory demyelinating disorder in Multiple Sclerosis (MS) is associated with acute seizures and epilepsy. Additionally, the likelihood of developing epilepsy increases with neurodegeneration. This study aims to reveal the clinical and radiological features of MS-epilepsy/seizure coexistence.</div></div><div><h3>Methods</h3><div>Among all patients diagnosed with MS that we followed in our center between April 2002 and July 2023, patients with a single seizure history or diagnosed with epilepsy (MS-seizure/epilepsy) were randomized 1:1 in terms of age and gender with MS patients without a diagnosis of epilepsy or seizures. Clinical (comorbidities, annualized relapse rate, disability, seizures during attacks, initial diagnosis, disease duration, disease-modifying therapies (DMTs), refractory epilepsy, anti-seizure drugs), electroencephalography (EEG) and MRI (lesion localization and new lesion(s)) data were retrospectively evaluated.</div></div><div><h3>Results</h3><div>The mean EDSS was 4.07±2.81. 29.4 % of patients had progressive MS (<em>n</em> = 10). Refractory epilepsy was 52.9 % (<em>n</em> = 18), and SE history was 14.7 % (<em>n</em> = 5). Pathology was detected in 69.7 % (<em>n</em> = 23) of patients in the EEG. The most common slow wave activation was detected in 51.5 % (<em>n</em> = 17). Refractory epilepsy was more common in cases under 45 and patients with lesions in thalamic localization. Lesions in the temporal and thalamic regions and cerebral atrophy were more common in the MS-seizure/epilepsy group.</div></div><div><h3>Conclusion</h3><div>Patients with demyelinating lesions in the temporal and thalamic regions should be questioned more carefully for epilepsy, and an EEG should be performed in case of clinical suspicion. Since thalamus lesions are more common in patients with refractory epilepsy, anti-seizure treatment strategies should be applied more carefully. The presence of atrophy on MRI confirms the link between neurodegeneration processes and the development of epilepsy.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105948"},"PeriodicalIF":2.9,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies","authors":"Sarah Conway ,&nbsp;Cory Dodson ,&nbsp;Gavin Hui ,&nbsp;C. William Pike ,&nbsp;Kristin Galetta","doi":"10.1016/j.msard.2024.105921","DOIUrl":"10.1016/j.msard.2024.105921","url":null,"abstract":"<div><div>This study investigates the occurrence of inflammatory vaginitis in women with Multiple Sclerosis (wwMS) undergoing B-cell depleting therapy versus other disease-modifying therapies (DMTs). Retrospective analysis of medical records from Stanford University between 2015–2023 shows similar rates of vaginitis in both groups, suggesting no significant association with B-cell therapy. Despite this, inflammatory vaginitis remains prevalent in both treatment groups, warranting further investigation into its mechanisms and management.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105921"},"PeriodicalIF":2.9,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment” [Multiple Sclerosis and Related Disorders, Volume 79, November 2023, 104949]","authors":"Sedat Sen ,&nbsp;Asli Tuncer ,&nbsp;Murat Terzi ,&nbsp;Sena Destan Bunul ,&nbsp;Pinar Ozen-Acar ,&nbsp;Burcu Altunrende ,&nbsp;Serkan Ozakbas ,&nbsp;Melih Tutuncu ,&nbsp;Ugur Uygunoglu ,&nbsp;Gulsen Akman-Demir ,&nbsp;Rana Karabudak ,&nbsp;Husnu Efendi ,&nbsp;Aksel Siva","doi":"10.1016/j.msard.2024.105917","DOIUrl":"10.1016/j.msard.2024.105917","url":null,"abstract":"","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105917"},"PeriodicalIF":2.9,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"9-HODE associates with thalamic atrophy and predicts white matter damage in multiple sclerosis","authors":"Wing Hee Fung ,&nbsp;Marike R. van Lingen ,&nbsp;Jelle Y. Broos ,&nbsp;Ka-Hoo Lam ,&nbsp;Maureen van Dam ,&nbsp;Wing Ka Fung ,&nbsp;Samantha Noteboom ,&nbsp;Ismail Koubiyr ,&nbsp;Helga E. de Vries ,&nbsp;Bas Jasperse ,&nbsp;Charlotte E. Teunissen ,&nbsp;Martin Giera ,&nbsp;Joep Killestein ,&nbsp;Hanneke E. Hulst ,&nbsp;Eva M.M. Strijbis ,&nbsp;Menno M. Schoonheim ,&nbsp;Gijs Kooij","doi":"10.1016/j.msard.2024.105946","DOIUrl":"10.1016/j.msard.2024.105946","url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is characterized by extensive tissue damage leading to a range of complex symptoms, including physical disability and cognitive dysfunction. Recent work has indicated the clinical relevance of bioactive lipid mediators (LMs), which are known to orchestrate inflammation and its resolution and are deregulated in MS. However, it is unknown whether LM profiles relate to white matter (WM) damage.</div></div><div><h3>Objectives</h3><div>To investigate the potential association between plasma-derived LMs and MRI-quantified WM damage using fractional anisotropy (FA) and grey matter (GM) atrophy in dimethyl fumarate-treated relapsing remitting MS (RRMS) patients.</div></div><div><h3>Methods</h3><div>Severity of FA-based WM damage and GM atrophy was determined in RRMS patients (<em>n</em> = 28) compared to age- and sex-matched controls (<em>n</em> = 31) at treatment initiation (baseline) and after 6 months. Plasma LMs were assessed using HPLC-MS/MS and baseline LMs were correlated to changes in FA and brain volumes.</div></div><div><h3>Results</h3><div>We observed significant WM damage in RRMS patients (mean age 41.4 [SD 9.1]) at baseline and follow-up (z-score=-0.33 and 0.31, respectively) compared to controls (mean age 41.9 [SD 9.5]; <em>p</em> &lt; 0.001 for both comparisons). Patients with severe WM damage showed a decline of thalamic volume (<em>p</em> = 0.02), and this decline correlated (<em>r</em> = 0.51, <em>p</em> &lt; 0.001) with lower baseline levels of 9-HODE. This LM also predicted FA worsening (beta = 0.14, <em>p</em> &lt; 0.001) over time at 6 months.</div></div><div><h3>Conclusion</h3><div>Despite the relatively small sample size, lower baseline levels of the LM 9-HODE correlated with more thalamic atrophy and predicted subsequent worsening of WM damage in RRMS patients.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105946"},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}